Cline Scientific AB (publ) ("Cline" or "the Company") has applied for and received conditional approval for admission to trading on the Nasdaq First North Growth Market ("Nasdaq First North"). As a result, the Company's delisting application has also been approved by Spotlight. The company's last day for trading on the Spotlight Stock Market is June 11, 2021. The first day for trading on Nasdaq First North is June 14, 2021. Shareholders in Cline Scientific will not have to take any action in connection with the list change.

Clines shares are currently traded on the Stocklight Stock Market. On March 10, 2021, the Company announced that the Board of Directors has decided to work to change the trading venue to Nasdaq First North in Stockholm.

Due to the list change, Cline Scientific has prepared a company description which will be published on the Company's website on June 8, 2021. The company description has only been prepared in connection with the application for admission to trading the shares on Nasdaq First North and does not contain any offer to the public to subscribe or otherwise acquire shares or other financial instruments in the Company, either in Sweden or in any other jurisdiction.

Cline Scientific's shares will continue to be traded under the short name CLINEB on Nasdaq First North.

Redeye AB has been appointed the Company's Certified Adviser on Nasdaq First North. In connection with the list change, Wistrand Advokatbyrå has acted as the Company's legal advisor.

For more information, please contact:
Patrik Sundh, CEO
Email: patrik.sundh@clinescientific.com
Phone: +46 703-585 088